Investment Rating - The report assigns a "Buy" rating for the company [2][5]. Core Views - The company achieved a revenue of 33.49 billion RMB for the first three quarters of 2024, representing a year-over-year increase of 14.2%. The net profit attributable to shareholders was 650 million RMB, up 195.2% year-over-year, which met expectations [3]. - In Q3 2024, the company reported a revenue of 11.92 billion RMB, a 16.3% increase year-over-year, with a net profit of 210 million RMB, reflecting a significant increase due to a low base from the previous year [3][4]. - The company continues to implement a price-for-volume strategy, resulting in a 28.0% increase in express delivery volume, totaling 5.88 billion packages [3][4]. Summary by Sections Financial Performance - The company's gross margin in Q3 was 5.4%, an increase of 2.3 percentage points year-over-year, attributed to improved capacity utilization and cost management [4]. - The net profit margin after deducting non-recurring items increased by approximately 1.2 percentage points to 1.69% in Q3, with a net profit of 200 million RMB, an increase of 210 million RMB year-over-year [4]. Future Outlook - The company has significant profit growth potential, with expectations to increase daily throughput capacity to over 75 million packages by 2024, up from the current average of 64 million [4]. - The report forecasts net profits of 910 million RMB, 1.26 billion RMB, and 1.51 billion RMB for 2024, 2025, and 2026 respectively, with year-over-year growth rates of 168%, 38%, and 20% [5][6]. Valuation Metrics - The current price-to-earnings (P/E) ratios for 2024, 2025, and 2026 are projected to be 19, 13, and 11 times respectively [5][6].

◼ 风险提示：原料价格上涨、终端销售不及预期、高端消费疲软 2024 年 10 月 31 日 王睿哲 C0062@capital.com.tw 目标价(元) 71 | --- | --- | --- | --- | |-----------------------|-----------------|----------------|-------------------------| | 公司基本信息 | | | | | 产业别 | | | 医药生物 | | A 股价 (2024/10/30) | | | 59.23 | | 深证成指 (2024/10/30) | | | 10530.85 | | 股价 12 个月高/低 | | | 69.46/42.59 | | 总发行股数 (百万) | | | 643.98 | | A 股数(百万 ) | | | 643.98 | | A 市值(亿元) | | | 381.43 | | 主要股东 | | | 华润东阿阿胶 | | 每股净值(元 ) | | | 有限公司 (23.50%) 15.39 | | 股价/账面净值 | | | 3.85 | | | 一个月 | 三 ...

Investment Rating - The report assigns a "BUY" rating for Yili Group (伊利股份) with a target price of 31 CNY [1]. Core Insights - The company reported a total revenue of 89.04 billion CNY for the first three quarters of 2024, a year-on-year decrease of 8.6%, while the net profit attributable to shareholders reached 10.87 billion CNY, an increase of 15.9% [1]. - The third quarter performance exceeded expectations, with revenue of 29.12 billion CNY, down 6.7% year-on-year, and a net profit of 3.34 billion CNY, up 8.5% year-on-year [1]. - The report highlights that the channel adjustments have concluded, and the low prices of raw milk have positively impacted profitability [5][6]. Summary by Sections Company Overview - Yili Group operates in the food and beverage industry, with a current stock price of 26.44 CNY as of October 30, 2024 [1]. - The company has a market capitalization of approximately 167.48 billion CNY and a price-to-book ratio of 2.99 [1]. Financial Performance - The revenue breakdown for Q3 shows liquid milk contributing 20.64 billion CNY (down 10.3% year-on-year), milk powder and dairy products at 6.82 billion CNY (up 6.6% year-on-year), and cold drinks at 1.02 billion CNY (down 16.7% year-on-year) [5]. - The gross margin for Q3 improved by 2.4 percentage points to 35%, attributed to low raw milk prices and improved product freshness following channel adjustments [5]. Profitability Forecast - The report slightly raises profit forecasts, expecting net profits of 12.22 billion CNY, 13.74 billion CNY, and 15.02 billion CNY for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 17.2%, 12.4%, and 9.4% [6][7]. - Earnings per share (EPS) are projected to be 1.92 CNY, 2.16 CNY, and 2.36 CNY for the same years, with corresponding price-to-earnings (P/E) ratios of 14, 12, and 11 [6][7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance [2][3][4]. Core Insights - The company reported a significant year-on-year revenue growth of 46.10% for the first three quarters of 2024, reaching 1.312 billion RMB, with a net profit of 393 million RMB, reflecting a 24.46% increase [2][4]. - The third quarter alone saw a revenue increase of 59.29% year-on-year, amounting to 515 million RMB, and a net profit surge of 97.20% year-on-year, totaling 159 million RMB [2][4]. - The company is expanding its production capacity, with ongoing projects expected to enhance its output in the next 2-3 years, particularly in polishing liquids and functional wet electronic chemicals [6][4]. Summary by Sections Company Overview - The company operates in the electronics sector, with a current stock price of 140.97 RMB and a market capitalization of 18.215 billion RMB [1]. - Major shareholder is Anji Microelectronics Co., Ltd., holding 30.81% of shares [1]. Financial Performance - The company achieved a gross margin of 58.56% in the first three quarters, an increase of 0.68 percentage points year-on-year [4][5]. - The report forecasts net profits of 560 million RMB, 748 million RMB, and 976 million RMB for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 39%, 34%, and 30% [6][8]. Product and Market Position - The product mix includes 84.4% from chemical mechanical polishing liquids and 6.4% from wet electronic chemicals, with a steady increase in market share for polishing liquids from 3% in 2020 to 8% by the end of 2023 [1][4]. - The company is successfully introducing new products, with some entering a growth phase, and is expected to further enhance its product structure and profitability [3][4]. Capacity Expansion - Current polishing liquid capacity stands at 29,100 tons, with additional capacities under construction expected to come online in the next few years [6]. - The company is also developing new production facilities for etching and plating liquids, which will contribute to its platform strategy in electronic materials [6].

| --- | --- | |----------------------|--------| | | | | 机构投资者占流通 A | 股比例 | | 基金 | 3.5% | | 一般法人 | 51.4% | 2024 年 10 月 30 日 王睿哲 C0062@capital.com.tw 目标价(元/港元) 31/18 | --- | --- | --- | --- | |-------------------------|----------|--------|----------------| | | | | | | | | | | | 公司基本资讯 | | | | | 产业别 | | | 医药生物 | | A 股价 (2024/10/29) | | | 26.04 | | 上证指数 (2024/10/29) | | | 3286.41 | | 股价 12 个月高 / 低 | | | 30.44/20.15 | | 总发行股数 ( 百万 ) | | | 2671.33 | | A 股数 ( 百万 ) | | | 2118.49 | | A 市值 ( 亿元 ) | | | 551.65 | | 主要股 ...

Investment Rating - The report assigns a "Trading Buy" rating to the company, with a target price of 64 CNY [2] Core Views - The company's new energy vehicle business continues to grow rapidly, while the industrial control business remains under pressure [2] - In 3Q24, the company achieved revenue of 92.1 billion CNY, a YoY increase of 20.1%, driven by strong growth in the new energy vehicle sector [2] - The new energy vehicle business contributed approximately 44 billion CNY in revenue, a YoY increase of 91%, benefiting from rapid sales growth of customer models [2] - The industrial automation business saw a 7% YoY decline in revenue, with specific segments like general inverters, general servos, and PLC&HMI experiencing drops of 2%, 15%, and 25% respectively [2] - The company's gross margin declined to 29.7% in 3Q24, down 5.3 percentage points YoY, primarily due to the increased proportion of low-margin new energy vehicle business [2] Financial Performance - For the first three quarters of 2024, the company reported revenue of 254.0 billion CNY, a YoY increase of 26.2%, and net profit attributable to shareholders of 33.5 billion CNY, a YoY increase of 1.0% [2] - In 3Q24, the company's net profit attributable to shareholders was 12.4 billion CNY, a slight YoY decrease of 0.5%, while non-GAAP net profit was 10.7 billion CNY, down 9.5% YoY [2] - The company's 3Q24 operating margin was 17.1%, down 1.9 percentage points YoY, mainly due to a decrease in R&D expense ratio [2] Business Segments - The new energy vehicle & rail transit segment accounted for 38.5% of the company's product mix, while the elevator electrical segment contributed 14.4% [2] - The general automation segment, which makes up 46.5% of the product mix, saw a decline in revenue, particularly in the PLC&HMI segment, which dropped by 25% YoY [2] Strategic Initiatives - The company is accelerating its internationalization strategy, establishing new subsidiaries and offices in Vietnam and building a new factory in Thailand [2] - In the digitalization space, the company showcased its industrial digital platform InoCube and the iFA Evolution software platform at the Industrial Expo, enhancing its competitiveness in software and hardware integration [2] - The recent acquisition of a French industrial software company is expected to complement the company's digital twin technology [2] Future Outlook - The report forecasts that the company will achieve net profits of 47, 58, and 69 billion CNY for 2024, 2025, and 2026 respectively, with EPS of 1.8, 2.2, and 2.6 CNY [2] - The company's PE ratios for 2024-2026 are projected at 32x, 27x, and 22x, based on the current A-share price [2]

阿 .................................................... 接续下页 ............................................................... 2024 年 10 月 29 日 顾向君 H70420@capitalcom.tw 目标价(元) 48 | --- | --- | --- | --- | |-----------------------|----------|----------------|------------------------------------| | 公司基本资讯 | | | | | 产业别 | | | 食品饮料 | | A 股价(2024/10/28) | | | 45.37 | | 上证指数 (2024/10/28) | | | 3322.20 | | 股价 12 个月高/低 | | | 52.99/32.41 | | 总发行股数(百万 | ) | | 5560.60 | | A 股数(百万 ) | | | 5560.60 | | A 市值(亿元) | | | 2522.8 ...

Investment Rating - The report assigns a "Trading Buy" rating to the company, indicating a potential upside of 5% to 15% based on current valuations [3][6]. Core Insights - The company reported a revenue of CNY 253.9 billion for the first three quarters of 2024, reflecting a year-over-year increase of 0.6%. The net profit attributable to shareholders was CNY 46.074 billion, down 4.5% year-over-year, but the performance exceeded expectations [3][4]. - In Q3 2024, the company achieved a revenue of CNY 85.8 billion, up 3% year-over-year and 7% quarter-over-quarter, with a net profit of CNY 16.57 billion, marking an 11% increase year-over-year and a 22% increase quarter-over-quarter [3][4]. - The coal segment's profit for Q3 was CNY 15.065 billion, up 19.3% year-over-year and quarter-over-quarter, with a gross margin of 31.2%, an increase of 3.7 percentage points year-over-year [4]. - The power generation segment reached a record high in electricity sales, generating a profit of CNY 3.18 billion in Q3, with a gross margin of 15.8% [4]. - The report anticipates net profits of CNY 60.3 billion, CNY 61.3 billion, and CNY 63.7 billion for 2024, 2025, and 2026 respectively, with year-over-year growth of 1%, 2%, and 4% [4][5]. Summary by Sections Company Overview - The company operates primarily in the mining sector, with coal revenue accounting for 68.8% of total income, followed by power generation at 25.5%, transportation at 4.3%, and coal chemical at 1.4% [3]. Financial Performance - The company’s A-share price as of October 25, 2024, was CNY 40.93, with a market capitalization of CNY 674.978 billion. The price-to-book ratio stands at 1.96, and the earnings per share (EPS) for 2024 is projected at CNY 3.03 [3][5]. - The company’s dividend per share (DPS) is expected to be CNY 2.27 for 2024, with an A-share dividend yield of 5.56% and an H-share yield of 7.49% [5]. Market Position - The company is a leading player in the domestic coal industry, benefiting from cost control and integrated coal-power operations. The current valuation is considered reasonable, supporting the "Trading Buy" rating [4].

.......................... 接续下页................................... 2024 年 10 月 28 日 王睿哲 C0062@capital.com.tw 目标价(元) 34 | --- | --- | --- | --- | --- | |-----------------------|------------|-------|---------------|----------------| | | | | | | | | | | | | | 公司基本资讯 | | | | | | 产业别 | | | | 医药生物 | | A 股价(2024/10/25) | | | | 26.45 | | 深证成指 (2024/10/25) | | | | 10619.85 | | 股价 12 个月高/低 | | | | 29.98/20.37 | | 总发行股数(百万 | ) | | | 1016.18 | | A 股数(百万 ) | | | | 881.79 | | A 市值(亿元) | | | | 233.23 | | 主要股东 | | | | 徐州恩华 ...

Investment Rating - The report assigns a "Trading Buy" rating for the company, indicating a potential upside of 5% to 15% [3][9]. Core Views - The company achieved a total revenue of RMB 120.78 billion for the first three quarters of 2024, representing a year-on-year increase of 17%, with a net profit of RMB 60.83 billion, up 15% year-on-year [3]. - The revenue from Moutai liquor reached RMB 101.13 billion, a 15.9% increase year-on-year, while series liquor revenue was RMB 19.4 billion, growing by 24.4% [3]. - The report highlights a stable performance in revenue and profit, with expectations for the company to meet its annual targets [3]. Summary by Sections Financial Performance - For Q3 2024, the company reported revenue of RMB 38.85 billion, a 15.3% increase year-on-year, and a net profit of RMB 19.13 billion, up 13% [3]. - The gross margin for the first three quarters was 91.7%, slightly down by 0.2 percentage points year-on-year [4]. Sales Channels - Direct sales generated approximately RMB 52 billion in revenue for the first three quarters, a 12.5% increase year-on-year, while traditional channels saw revenue of RMB 68.53 billion, up 21% [4]. - In Q3, direct sales revenue was RMB 18.26 billion, a 23.5% increase year-on-year, while traditional channels generated RMB 20.54 billion, a 9.7% increase [4]. Profit Forecast - The report slightly lowers profit forecasts for 2024-2026, expecting net profits of RMB 86.2 billion, RMB 97.86 billion, and RMB 108.45 billion, respectively, with year-on-year growth rates of 15.3%, 13.5%, and 10.8% [5]. - The expected earnings per share (EPS) for 2024-2026 are RMB 68.62, RMB 77.90, and RMB 86.33, with corresponding price-to-earnings (P/E) ratios of 23, 20, and 18 [5][8].